Pathology of Urologic Cancers
Author Contributions
Funding
Conflicts of Interest
References
- Campagna, R.; Pozzi, V.; Spinelli, G.; Sartini, D.; Milanese, G.; Galosi, A.B.; Emanuelli, M. The Utility of Nicotinamide N-Methyltransferase as a Potential Biomarker to Predict the Oncological Outcomes for Urological Cancers: An Update. Biomolecules 2021, 11, 1214. [Google Scholar] [CrossRef]
- Paramanantham, Y.; Chung, I.; Said, N.A.B. The role of tumour microenvironment-driven miRNAs in the chemoresistance of muscle-invasive bladder cancer-a review. Urol. Oncol. 2022, 40, 133–148. [Google Scholar] [CrossRef]
- Mickisch, G.H. Chemoresistance of renal cell carcinoma: 1986–1994. World J. Urol. 1994, 12, 214–223. [Google Scholar] [CrossRef] [Green Version]
- Culig, Z. miRNA as Regulators of Prostate Carcinogenesis and Endocrine and Chemoresistance. Curr. Cancer Drug Targets 2021, 21, 283–288. [Google Scholar] [CrossRef]
- Mazzucchelli, R.; Marzioni, D.; Tossetta, G.; Pepi, L.; Montironi, R. Bladder Cancer Sample Handling and Reporting: Pathologist’s Point of View. Front. Surg. 2021, 8, 754741. [Google Scholar] [CrossRef]
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30. [Google Scholar] [CrossRef]
- Marzioni, D.; Lorenzi, T.; Mazzucchelli, R.; Capparuccia, L.; Morroni, M.; Fiorini, R.; Bracalenti, C.; Catalano, A.; David, G.; Castellucci, M.; et al. Expression of basic fibroblast growth factor, its receptors and syndecans in bladder cancer. Int. J. Immunopathol. Pharmacol. 2009, 22, 627–638. [Google Scholar] [CrossRef]
- Tossetta, G.; Fantone, S.; Gesuita, R.; Montironi, R.; Marzioni, D.; Mazzucchelli, R. AT-rich interactive domain 1A (ARID1A) cannot be considered a morphological marker for prostate cancer progression: A pilot study. Acta Histochem. 2022, 124, 151847. [Google Scholar] [CrossRef]
- Cimadamore, A.; Gasparrini, S.; Santoni, M.; Cheng, L.; Lopez-Beltran, A.; Battelli, N.; Massari, F.; Giunchi, F.; Fiorentino, M.; Scarpelli, M.; et al. Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer. Expert Rev. Mol. Diagn. 2018, 18, 645–655. [Google Scholar] [CrossRef]
- Montironi, R.; Cheng, L.; Cimadamore, A.; Lopez-Beltran, A. Molecular diagnostics in uro-oncology. Expert Rev. Mol. Diagn. 2020, 20, 117–121. [Google Scholar] [CrossRef] [Green Version]
- Pozzi, V.; Di Ruscio, G.; Sartini, D.; Campagna, R.; Seta, R.; Fulvi, P.; Vici, A.; Milanese, G.; Brandoni, G.; Galosi, A.B.; et al. Clinical performance and utility of a NNMT-based urine test for bladder cancer. Int. J. Biol. Markers 2018, 33, 94–101. [Google Scholar] [CrossRef] [PubMed]
- Ganzetti, G.; Sartini, D.; Campanati, A.; Rubini, C.; Molinelli, E.; Brisigotti, V.; Cecati, M.; Pozzi, V.; Campagna, R.; Offidani, A.; et al. Nicotinamide N-methyltransferase: Potential involvement in cutaneous malignant melanoma. Melanoma Res. 2018, 28, 82–88. [Google Scholar] [CrossRef] [PubMed]
- Campagna, R.; Pozzi, V.; Sartini, D.; Salvolini, E.; Brisigotti, V.; Molinelli, E.; Campanati, A.; Offidani, A.; Emanuelli, M. Beyond Nicotinamide Metabolism: Potential Role of Nicotinamide N-Methyltransferase as a Biomarker in Skin Cancers. Cancers 2021, 13, 4943. [Google Scholar] [CrossRef] [PubMed]
- Fujita, K.; Nonomura, N. Urinary biomarkers of prostate cancer. Int. J. Urol. 2018, 25, 770–779. [Google Scholar] [CrossRef] [Green Version]
- Bacchetti, T.; Salvolini, E.; Pompei, V.; Campagna, R.; Molinelli, E.; Brisigotti, V.; Togni, L.; Lucarini, G.; Sartini, D.; Campanati, A.; et al. Paraoxonase-2, A potential biomarker for skin cancer aggressiveness. Eur. J. Clin. Investig. 2021, 51, e13452. [Google Scholar] [CrossRef]
- Sartini, D.; Campagna, R.; Lucarini, G.; Pompei, V.; Salvolini, E.; Mattioli-Belmonte, M.; Molinelli, E.; Brisigotti, V.; Campanati, A.; Bacchetti, T.; et al. Differential immunohistochemical expression of paraoxonase-2 in actinic keratosis and squamous cell carcinoma. Hum. Cell 2021, 34, 1929–1931. [Google Scholar] [CrossRef]
- Liu, Z.; Zhong, J.; Cai, C.; Lu, J.; Wu, W.; Zeng, G. Immune-related biomarker risk score predicts prognosis in prostate cancer. Aging 2020, 12, 22776–22793. [Google Scholar] [CrossRef]
- Zhang, D.; Du, D.; Yi, S.; Li, X. LncRNA PCAT6, A potential biomarker for diagnosis and prognosis of bladder cancer. Ann. Diagn. Pathol. 2020, 49, 151642. [Google Scholar] [CrossRef]
- Campagna, R.; Bacchetti, T.; Salvolini, E.; Pozzi, V.; Molinelli, E.; Brisigotti, V.; Sartini, D.; Campanati, A.; Ferretti, G.; Offidani, A.; et al. Paraoxonase-2 Silencing Enhances Sensitivity of A375 Melanoma Cells to Treatment with Cisplatin. Antioxidants 2020, 9, 1238. [Google Scholar] [CrossRef]
- Campagna, R.; Salvolini, E.; Pompei, V.; Pozzi, V.; Salvucci, A.; Molinelli, E.; Brisigotti, V.; Sartini, D.; Campanati, A.; Offidani, A.; et al. Nicotinamide N-methyltransferase gene silencing enhances chemosensitivity of melanoma cell lines. Pigment. Cell Melanoma Res. 2021, 34, 1039–1048. [Google Scholar] [CrossRef]
- Su, Y.; Feng, W.; Shi, J.; Chen, L.; Huang, J.; Lin, T. circRIP2 accelerates bladder cancer progression via miR-1305/Tgf-beta2/smad3 pathway. Mol. Cancer 2020, 19, 23. [Google Scholar] [CrossRef] [Green Version]
- Kancherla, P.; Daneshvar, M.; Sager, R.A.; Mollapour, M.; Bratslavsky, G. Fumarate hydratase as a therapeutic target in renal cancer. Expert Opin. Ther. Targets 2020, 24, 923–936. [Google Scholar] [CrossRef]
- Tossetta, G.; Fantone, S.; Montanari, E.; Marzioni, D.; Goteri, G. Role of NRF2 in Ovarian Cancer. Antioxidants 2022, 11, 663. [Google Scholar] [CrossRef]
- Avellini, C.; Licini, C.; Lazzarini, R.; Gesuita, R.; Guerra, E.; Tossetta, G.; Castellucci, C.; Giannubilo, S.R.; Procopio, A.; Alberti, S.; et al. The trophoblast cell surface antigen 2 and miR-125b axis in urothelial bladder cancer. Oncotarget 2017, 8, 58642–58653. [Google Scholar] [CrossRef] [Green Version]
- Campagna, R.; Cecati, M.; Pozzi, V.; Fumarola, S.; Pompei, V.; Milanese, G.; Galosi, A.B.; Sartini, D.; Emanuelli, M. Involvement of transforming growth factor beta 1 in the transcriptional regulation of nicotinamide N-methyltransferase in clear cell renal cell carcinoma. Cell Mol. Biol. 2018, 64, 51–55. [Google Scholar] [CrossRef]
- Manini, C.; Lopez, J.I. The Labyrinth of Renal Cell Carcinoma. Cancers 2020, 12, 521. [Google Scholar] [CrossRef] [Green Version]
- Jonasch, E.; Walker, C.L.; Rathmell, W.K. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat. Rev. Nephrol. 2021, 17, 245–261. [Google Scholar] [CrossRef]
- Baumgart, S.; Holters, S.; Ohlmann, C.H.; Bohle, R.; Stockle, M.; Ostenfeld, M.S.; Dyrskjot, L.; Junker, K.; Heinzelmann, J. Exosomes of invasive urothelial carcinoma cells are characterized by a specific miRNA expression signature. Oncotarget 2017, 8, 58278–58291. [Google Scholar] [CrossRef] [Green Version]
- Na, R.; Zheng, S.L.; Han, M.; Yu, H.; Jiang, D.; Shah, S.; Ewing, C.M.; Zhang, L.; Novakovic, K.; Petkewicz, J.; et al. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur. Urol. 2017, 71, 740–747. [Google Scholar] [CrossRef] [Green Version]
- Barrera, G. Oxidative stress and lipid peroxidation products in cancer progression and therapy. ISRN Oncol. 2012, 2012, 137289. [Google Scholar] [CrossRef] [Green Version]
- Papadakos, S.P.; Dedes, N.; Kouroumalis, E.; Theocharis, S. The Role of the NLRP3 Inflammasome in HCC Carcinogenesis and Treatment: Harnessing Innate Immunity. Cancers 2022, 14, 3150. [Google Scholar] [CrossRef]
- Emanuelli, M.; Sartini, D.; Molinelli, E.; Campagna, R.; Pozzi, V.; Salvolini, E.; Simonetti, O.; Campanati, A.; Offidani, A. The Double-Edged Sword of Oxidative Stress in Skin Damage and Melanoma: From Physiopathology to Therapeutical Approaches. Antioxidants 2022, 11, 612. [Google Scholar] [CrossRef]
- Fumarola, S.; Cecati, M.; Sartini, D.; Ferretti, G.; Milanese, G.; Galosi, A.B.; Pozzi, V.; Campagna, R.; Morresi, C.; Emanuelli, M.; et al. Bladder Cancer Chemosensitivity is Affected by Paraoxonase-2 Expression. Antioxidants 2020, 9, 175. [Google Scholar] [CrossRef] [Green Version]
- Taucher, E.; Mykoliuk, I.; Fediuk, M.; Smolle-Juettner, F.M. Autophagy, Oxidative Stress and Cancer Development. Cancers 2022, 14, 1637. [Google Scholar] [CrossRef]
- Gupta, M.; Chandan, K.; Sarwat, M. Natural Products and their Derivatives as Immune Check Point Inhibitors: Targeting Cytokine/Chemokine Signalling in Cancer. Semin. Cancer Biol. 2022; in press. [Google Scholar] [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tossetta, G.; Mazzucchelli, R. Pathology of Urologic Cancers. Cancers 2022, 14, 3751. https://doi.org/10.3390/cancers14153751
Tossetta G, Mazzucchelli R. Pathology of Urologic Cancers. Cancers. 2022; 14(15):3751. https://doi.org/10.3390/cancers14153751
Chicago/Turabian StyleTossetta, Giovanni, and Roberta Mazzucchelli. 2022. "Pathology of Urologic Cancers" Cancers 14, no. 15: 3751. https://doi.org/10.3390/cancers14153751
APA StyleTossetta, G., & Mazzucchelli, R. (2022). Pathology of Urologic Cancers. Cancers, 14(15), 3751. https://doi.org/10.3390/cancers14153751